Marco de Bruyn
Affiliation: University Medical Center Groningen
Country: The Netherlands
- Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjectsPaul Eggleton
Peninsula Medical School, University of Exeter, Heavitree Road, Exeter EX1 2LU, UK
Arthritis Res Ther 13:R208. 2011..g., anti-CD20 antibodies, to alleviate RA is unclear. This study examined the proportions of IL-17-secreting lymphocytes in the blood of healthy subjects and RA patients and determined if Th17 cells belong to a CD20+ subset of T cells...
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivoMarco de Bruyn
Surgical Research Laboratories, Department of Surgery, University Medical Center Groningen Hanzeplein 1, University of Groningen, Groningen 9713 GZ, The Netherlands
Mol Cancer 9:301. 2010..Anti-MCSP:TRAIL was designed to 1. selectively accrete at the cell surface of MCSP-positive melanoma cells and inhibit MCSP tumorigenic signaling and 2. activate apoptotic TRAIL-signaling...
- Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in ratsYunwei Wei
Third Department of General Surgery, First Clinical Hospital Harbin, Harbin Medical University, Harbin 150001, Heilongjiang, China
BMC Gastroenterol 10:42. 2010..Here, we assessed whether CO released from CORM-2 protects against hepatic I/Ri in a rat model...
- Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cellsMarco de Bruyn
Department of Surgery, Surgical Research Laboratories, University Medical Center Groningen UMCG, University of Groningen, Groningen, The Netherlands
Clin Cancer Res 17:5626-37. 2011..Here, we present a novel strategy designed to selectively enhance the tumoricidal activity of T cells by targeted delivery of TNF-related apoptosis-inducing ligand (TRAIL) to the T-cell surface...
- Antibody-based fusion proteins to target death receptors in cancerMarco de Bruyn
Department of Surgery, Surgical Research Laboratories, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
Cancer Lett 332:175-83. 2013..Importantly, off-target binding by scFv:sTRAIL to normal cells showed no signs of toxicity. In this review, we highlight the rationale and perspectives of scFv:TRAIL/scFv:sFasL based fusion proteins for cancer therapy...
- In vivo responses of human A375M melanoma to a σ ligand: 18F-FDG PET imagingAnna A Rybczynska
University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands
J Nucl Med 54:1613-20. 2013..Here, we aimed to assess whether the σ-ligand rimcazole inhibits growth of A375M melanoma xenografts in nude mice and whether rimcazole treatment changes (18)F-FDG uptake in vivo...
- Therapeutic potential of Galectin-9 in human diseaseValerie R Wiersma
Department of Surgery, Surgical Research Laboratories, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Med Res Rev 33:E102-26. 2013..Here, we review the biology and physiological role of this versatile lectin and discuss the therapeutic potential of Gal-9 in various diseases, including autoimmunity, asthma, infection, and cancer...
- Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell deathKim L Brunekreeft
Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Mol Cancer 13:85. 2014..Although CD40 agonists have clinical activity in humans, the associated systemic activation of the immune system triggers dose-limiting side-effects...
- Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signalingEdwin Bremer
Department of Surgery, Surgical Research Laboratory, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Immunol Lett 138:161-8. 2011..These findings indicate that scFvCD7:sFasL may be of therapeutic value for the selective elimination of pathogenic synovial T-cells of the T(H1) subtype in both RA and JIA...